Swiss Group for Clinical Cancer Research

4 trials 1 recruiting Academic / non-commercial

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

2 Completed trials

3 Countries active

14 Unique IMPs

100% Results reported

Phase II

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer stage III 1 Testicular seminoma (pure) stage II 1

Top IMPs

CARBOPLATIN 2 CISPLATIN 2 DOCETAXEL 2 ACALABRUTINIB 1 CABAZITAXEL 1 DAROLUTAMIDE 1 DURVALUMAB 1 ETOPOSIDE 1 LUTETIUM (177LU) OXODOTREOTIDE 1 OLAPARIB 1 PACLITAXEL 1 PEMETREXED 1

All trials

4 total

SAKK 38/19: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial Pending

2024-516740-26-00 Phase II 1 country ACALABRUTINIB
SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial Recruiting

2024-512132-29-00 Phase II 1 country CABAZITAXEL; DAROLUTAMIDE; DOCETAXEL; LUTETIUM (177LU) OXODOTREOTIDE; OLAPARIB; …
Radiotherapy to enhance the effects of an immune therapy before tumor surgery in patients with advanced non-small cell lung cancer (NSCLC). … Ended

2023-504536-18-00 Phase II 1 country CARBOPLATIN; CISPLATIN; DOCETAXEL; DURVALUMAB; PACLITAXEL; PEMETREXED; VINORELBI…
Reduced intensity radio-chemotherapy for stage IIA/B seminoma Ended

2023-509663-24-00 Phase II 1 country CARBOPLATIN; CISPLATIN; ETOPOSIDE

Showing 1–4 of 4 trials

← All sponsors A–Z